These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 38492197)
1. Isolated salivary gland extramedullary relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia during blinatumomab treatment. Kawakami Y; Imamura M; Imai C Int J Hematol; 2024 May; 119(5):479-480. PubMed ID: 38492197 [No Abstract] [Full Text] [Related]
2. Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER study. Jabbour E; Patel K; Jain N; Duose D; Luthra R; Short NJ; Zugmaier G; San Lucas A; Velasco K; Tran Q; Zaman F; Konopleva M; Kantarjian H Am J Hematol; 2021 Oct; 96(10):E379-E383. PubMed ID: 34161631 [No Abstract] [Full Text] [Related]
3. The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or Philadelphia chromosome-like acute lymphoblastic leukemia. Wu X; Lu S; Zhang X; Yang Z; Sun A; Wu D; Zhou H; Miao M Cancer Med; 2024 Sep; 13(17):e70161. PubMed ID: 39240182 [TBL] [Abstract][Full Text] [Related]
4. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. Brown PA; Ji L; Xu X; Devidas M; Hogan LE; Borowitz MJ; Raetz EA; Zugmaier G; Sharon E; Bernhardt MB; Terezakis SA; Gore L; Whitlock JA; Pulsipher MA; Hunger SP; Loh ML JAMA; 2021 Mar; 325(9):833-842. PubMed ID: 33651090 [TBL] [Abstract][Full Text] [Related]
5. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment. Demosthenous C; Lalayanni C; Iskas M; Douka V; Pastelli N; Anagnostopoulos A Curr Probl Cancer; 2019 Jun; 43(3):222-227. PubMed ID: 29895435 [TBL] [Abstract][Full Text] [Related]
7. A balancing act: Blinatumomab use in a rare occurrence of Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia in an adolescent patient with Down syndrome. Rav ES; Wahba A; Patnaik A; Toruner G; Hittle A; Toepfer L; Roth M; Cuglievan B; Nunez C; McCall D Pediatr Blood Cancer; 2023 May; 70(5):e30191. PubMed ID: 36602024 [No Abstract] [Full Text] [Related]
8. Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Lee S Cancer Med; 2019 Dec; 8(18):7650-7659. PubMed ID: 31691536 [TBL] [Abstract][Full Text] [Related]
9. Venetoclax and blinatumomab based chemotherapy-free treatment in a patient with Philadelphia chromosome-negative acute lymphoblastic leukemia. Chang J; Shen YJ; Shi T; Wang HF; Jin J; Zhu HH Ann Hematol; 2023 May; 102(5):1275-1277. PubMed ID: 36892592 [No Abstract] [Full Text] [Related]
10. Characterization of relapse patterns in patients with acute lymphoblastic leukemia treated with blinatumomab. Lau KM; Saunders IM; Goodman AM J Oncol Pharm Pract; 2021 Jun; 27(4):821-826. PubMed ID: 32605497 [TBL] [Abstract][Full Text] [Related]
11. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800 [TBL] [Abstract][Full Text] [Related]
12. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Schlegel P; Lang P; Zugmaier G; Ebinger M; Kreyenberg H; Witte KE; Feucht J; Pfeiffer M; Teltschik HM; Kyzirakos C; Feuchtinger T; Handgretinger R Haematologica; 2014 Jul; 99(7):1212-9. PubMed ID: 24727818 [TBL] [Abstract][Full Text] [Related]
13. Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study. Lee SH; Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Lee JW; Lee S Int J Hematol; 2022 Jan; 115(1):135-139. PubMed ID: 34617186 [TBL] [Abstract][Full Text] [Related]
14. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia. King AC; Pappacena JJ; Tallman MS; Park JH; Geyer MB Leuk Res; 2019 Apr; 79():27-33. PubMed ID: 30831480 [TBL] [Abstract][Full Text] [Related]
15. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. Locatelli F; Zugmaier G; Rizzari C; Morris JD; Gruhn B; Klingebiel T; Parasole R; Linderkamp C; Flotho C; Petit A; Micalizzi C; Mergen N; Mohammad A; Kormany WN; Eckert C; Möricke A; Sartor M; Hrusak O; Peters C; Saha V; Vinti L; von Stackelberg A JAMA; 2021 Mar; 325(9):843-854. PubMed ID: 33651091 [TBL] [Abstract][Full Text] [Related]
16. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia. Rambaldi A; Ribera JM; Kantarjian HM; Dombret H; Ottmann OG; Stein AS; Tuglus CA; Zhao X; Kim C; Martinelli G Cancer; 2020 Jan; 126(2):304-310. PubMed ID: 31626339 [TBL] [Abstract][Full Text] [Related]
17. Blinatumomab (Blincyto) for acute lymphoblastic leukemia. Med Lett Drugs Ther; 2015 May; 57(1468):e74-5. PubMed ID: 25941958 [TBL] [Abstract][Full Text] [Related]
18. Blinatumomab for the treatment of adult acute lymphoblastic leukemia. Dahl J; Mace M; Kantarjian H; Jabbour E Drugs Today (Barc); 2015 Apr; 51(4):231-41. PubMed ID: 26020065 [TBL] [Abstract][Full Text] [Related]
19. Relapsed Philadelphia Chromosome-Positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy Successfully Treated with Combination of Blinatumomab and Ponatinib. El Chaer F; Holtzman NG; Sausville EA; Law JY; Lee ST; Duong VH; Baer MR; Koka R; Singh ZN; Hardy NM; Emadi A Acta Haematol; 2019; 141(2):107-110. PubMed ID: 30695783 [TBL] [Abstract][Full Text] [Related]
20. Successful use of blinatumomab in a patient with acute lymphoblastic leukemia and severe hepatic dysfunction. Robinson AC; Marini BL; Pettit KM; Perissinotti AJ J Oncol Pharm Pract; 2020 Jan; 26(1):200-205. PubMed ID: 30760167 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]